Debbie Rigby takes a look at the latest in research news
Meta-analysis of 17 RCTs shows no association between dose-specific omega-3 supplementation and CVD outcomes. Omega-3 supplementation at a dose of <2g/day was not associated with any outcome including all-cause mortality and cardiac death. evidence for higher doses (2–4 1 g capsules/day) was weak.
People with schizophrenia have higher rates of smoking than the general population, and lower quit rates. This systematic review concluded that varenicline might be superior to bupropion; however, additional direct testing and combination trials of pharmacological agents for smoking cessation are required to inform clinical decision making for people with psychosis.
Lancet Psychiatry 2020.
Patients with chronic obstructive pulmonary disease are undertreated with beta-blockers following myocardial infarction, possibly due to fear for acute exacerbations of COPD. In a Danish nationwide study of patients with COPD following hospitalisation for MI, beta-blocker use was not associated with increased risk of acute exacerbations of COPD following MI. This finding was independent of COPD severity, symptom burden and exacerbation history, and supports the safety of beta-blockers in patients with COPD, including high-risk patients with severe disease.
Heart failure with preserved ejection fraction (HFpEF) has no universally accepted therapies that alter the clinical course of condition. Current guidelines for the management of HFpEF focus on the treatment of underlying conditions (eg hypertension or atrial fibrillation). Diuretics are recommended for the relief of symptoms.
Therapeutics and Clinical Risk Management 2020;1:769–785.